MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alaeddin Ahram as Executive Vice President, International. Mr. Ahram possesses more than 25 years of leadership experience and successes in building new markets and accelerating commercialization for novel medical devices across Asia, Europe, and the Middle East.
Prior to joining Elixir Medical, Mr. Ahram held several senior executive roles at Smith & Nephew, including Senior Vice President and Managing Director of the Greater China region, and Senior Vice President of the Advanced Surgical Devices business, Emerging Markets, where he led double-digit growth of the business. Previously, he held several senior executive and management roles at Medtronic. As Vice President, Cardiovascular, International, he managed and grew a global business that launched the Endeavor drug-eluting stent. In his roles as Vice President of Acquisition Integration Activities, Europe and Central Asia, and as Head of International Commercial Operations for Medtronic Invatec, he brought innovative cardiovascular products for coronary and peripheral treatment to new markets.
“As we introduce and expand commercialization of the DynamX Bioadaptor in markets around the world and build our commercial infrastructure, we are relying on Ala’s rich experience and expertise to accelerate our success,” said Elixir Medical President and Chief Operating Officer, Vinayak Bhat, PhD. “His track record of double-digit growth in international markets and his understanding of the interventional marketplace will be an invaluable addition to our strong management team.”
“I am excited about leveraging my extensive international experience to help make the company’s extraordinary technology accessible to more patients and accelerate its adoption by leading clinicians and clinics globally,” said Ahram.
About Elixir Medical
Elixir Medical Corporation, a privately-funded company based in Milpitas, California, develops next-generation platforms to treat coronary and peripheral artery disease that are designed to restore the adaptive remodeling and pulsatile motion capabilities of the blood vessel. The company’s mission is to transform the care of patients with heart and vascular disease through innovation.
The DynamX Coronary Bioadaptor System is CE Mark approved. Not available for sale in the USA.
